CLINICAL CASE OF FAMILIAL DUCHENNE MYODYSTROPHY
Main Article Content
Abstract
The article presents an analysis of a clinical case of the diagnosis of familial Duchenne myodystrophy in a newborn child confirmed in the neonatal period. The stages of diagnosis and their peculiarities are described. The first stage of diagnosis of familial Duchenne myodystrophy in our clinical observation was accidentally identified changes in the blood biochemical analysis of the newborn on the second day of life: high activity of aspartate aminotransferase, serum alanine aminotransferase. Later, anamnestic data were analyzed - as it turned out, there was already a child with Duchenne myodystrophy in the family. However, child's mother was not alert to the possibility of having another child with similar pathology: she was registered at 24 weeks late for pregnancy, prenatal diagnostics of hereditary diseases was not carried out in this pregnancy (shown at 12 weeks of pregnancy), genetic examination of a woman to detect carrier mutation in Duchenne myodystrophy gene was not carried out.
Further, repeated targeted blood tests revealed increased creatine phosphokinase and lactate dehydrogenase activity. Finally, molecular-genetic examination confirmed a hereditary pathology – Duchenne myodystrophy in a newborn.
The aim of the article is to present a clinical family case of progressive Duchenne muscular dystrophy and to show the peculiarities and difficulties of diagnosing this genetic pathology in the neonatal period.
Conclusion. The description of a clinical case of familial Duchenne myodystrophy diagnosis in a newborn child confirmed in the neonatal period is a rare situation. The peculiarities of this case are shown taking into account the social status of the mother, anamnestic data, early blood biochemical changes. Two important, decisive and determining facts for deepening the diagnostic search (conducting a molecular genetic study) were two circumstances: a significant increase in the activity of the enzymes aspartate aminotransferase, serum alanine aminotransferase, creatine phosphokinase, lactate dehydrogenase and a history with an established diagnosis of familial Duchenne myodystrophy in a sibling.
Downloads
Article Details
Issue
Section
References
Evtushenko SK, Shaimurzin MR. Modified standards for the diagnosis of neuromuscular diseases. Cerebral palsy and other movement disorders in children: Materials of the international conference. M., 2011. P. 54-55. Russian (Евтушенко С.К., Шаймурзин М.Р. Модифицированные стандарты диагностики нервно-мышечных заболеваний //Детский церебральный паралич и другие нарушения движения у детей: Матер. междунар. конф. М., 2011. С. 54-55)
Sewry CA. Muscular dystrophies: an update on pathology and diagnosis. Acta Neuropathol. 2010; 120(3): 343-358
Zhdanova EB, Kharmalov DA, Belousova ED. Somatic disorders in duchenne muscular dystrophy. Russian Bulletin of perinatology and pediatrics. 2011; 5: 46-50. Russian (Жданова Е.Б., Харламов Д.А., Белоусов Е.Д. Соматические нарушения при прогрессирующей дистрофии Дюшенна //Российский вестник перинатологии и педиатрии. 2011. № 5. С. 46-50)
Bloetzer C, Fluss J, Jeannet PY. Therapeutic trials for Duchenne muscular dystrophy: between hopes and disappointments. Rev Med Suisse. 2012; 8(329): 409-412
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018; 17(4): 347-361. doi: 10.1016/S1474-4422(18)30025-5
Nosko AS, Kurenkov AL, Nikitin SS, Zykov VP.Adequate managment of patients with dystrophinopathies (muscular dystrophy Duchenne/Becker: objective scales and additional diagnostic methods. Neuromuscular Diseases. 2014; 3: 13-19. Russian (Носко А.С., Куренков А.Л., Никитин С.С., Зыков В.П. Адекватный менеджмент пациентов с дистрофинопатиями (мышечная дистрофия Дюшенна/Беккера): применение объективизирующих шкал и дополнительных методов исследования //Нервно-мышечные болезни. 2014. № 3. С. 13-19)
Saito T, Kawai M, Kimura E, et al. Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan. Neuromuscul Disord. 2017; 27(2): 107-114. doi: 10.1016/j.nmd.2016.11.012
Evtushenko SK, Morozova TM, Shestova EP, Evtushenko OS. Syndrome of muscular hypotension in newborns and young children. Donetsk, 2008. 240 p. Russian (Евтушенко С.К., Морозова Т.М., Шестова Е.П., Евтушенко О.С. Синдром мышечной гипотонии у новорожденных и детей раннего возраста. Донецк, 2008. 240 с.)
Shaymurzin MR. New modified standards of diagnostics and therapy of myelino- and axonopathies in children with hereditary motor-sensory neuropathies (scientific review and own observations). International Neurological Journal. 2012; 1(47): 11-22. Russian (Шаймурзин М.Р. Новые модифицированные стандарты диагностики и терапии миелино- и аксонопатий у детей с наследственными мотосенсорными невропатиями (научный обзор и личные наблюдения) //Международный неврологический журнал. 2012. № 1(47). С. 11-22)
Shatillo AV. Histochemical diagnosis in clinical picture of rare neuromuscular disorders brief information and case reports. International Neurological Journal. 2013; 1(55): 21-24. Russian (Шатилло А.В. Гистохимическая диагностика в клинике редких нервномышечных заболеваний //Международный неврологический журнал. 2013. № 1(55). С. 21-24)
Bertini E, D'Amico A, Gualandi F, Petrini S. Congenital muscular dystrophies: a brief review. Semin Pediatr Neurol. 2011; 18(4): 277-288
Aatsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016; 53(3): 145-151. doi: 10.1136/jmedgenet-2015-103387
Gloss D, Moxley RT, Ashwal S, et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(5): 465-472. doi: 10.1212/WNL.0000000000002337